Literature DB >> 8895288

A comparison of cisatracurium and atracurium: onset of neuromuscular block after bolus injection and recovery after subsequent infusion.

H Mellinghoff1, L Radbruch, C Diefenbach, W Buzello.   

Abstract

Cisatracurium is a new nondepolarizing muscle relaxant. In patients randomized to receive either cisatracurium (n = 40) or atracurium (n = 20) we compared the time course of neuromuscular block. The initial bolus dose of cisatracurium was 0.1 mg/kg, that of atracurium 0.5 mg/kg. Neuromuscular block, maintained with an infusion of either drug, was reversed with neostigmine 45 micrograms/kg and atropine 20 micrograms/kg in one half of the patients. Neuromuscular transmission was assessed by recording the mechanical twitch response to train-of-four nerve stimulation. Onset times were 3.1 +/- 1.0 min with cisatracurium and 2.3 +/- 1.1 min with atracurium (P = 0.008). The infusion rates for a 95% +/- 4% neuromuscular block were 1.5 +/- 0.4 micrograms.kg-1.min-1 for cisatracurium and 6.6 +/- 1.7 micrograms.kg-1.min-1 for atracurium, 3.3 times those of cisatracurium when referenced to the active cations. After the infusion, the spontaneous recovery intervals 25%-75% of 18 +/- 11 min and 18 +/- 8 min for cisatracurium and atracurium (P = 0.896) were shortened to 5 +/- 2 min and 4 +/- 3 min (P = 0.921) after neostigmine. While attributing different onset times also to differences in the initial doses, we conclude that time profiles for neuromuscular block of both muscle relaxants, when given in equipotent doses, are not different.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895288     DOI: 10.1097/00000539-199611000-00030

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  14 in total

Review 1.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Altered pharmacodynamics and pharmacokinetics of cisatracurium in patients with severe mitral valve regurgitation during anaesthetic induction period.

Authors:  Jiayi Liu; Chunying Lu; Qirong Zou; Sheng Wang; Xuemei Peng
Journal:  Br J Clin Pharmacol       Date:  2016-10-16       Impact factor: 4.335

Review 3.  Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.

Authors:  H M Bryson; D Faulds
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

Review 4.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Cisatracurium in different doses versus atracurium during general anesthesia for abdominal surgery.

Authors:  A M El-Kasaby; H M Atef; A M Helmy; M Abo El-Nasr
Journal:  Saudi J Anaesth       Date:  2010-09

6.  [Feedback control of muscle relaxation with a varying on-off controller using cisatracurium].

Authors:  B Pohl; R Hofmockel; O Simanski; K Wende; B P Lampe
Journal:  Anaesthesist       Date:  2004-01       Impact factor: 1.041

7.  Effects on Intubating Conditions of Pretreatment with Remifentanil before Administration of Cisatracurium.

Authors:  Hye Jin Jeong; Seong Heon Lee; Hwi Jin Kim; Sang Hyun Kwak
Journal:  Chonnam Med J       Date:  2012-08-24

8.  Effect of isoflurane versus propofol-remifentanil anesthesia on neuromuscular blockade and hemodynamic responses by cisatracurium bolus injection.

Authors:  Dongho Hyun; Han-Bom Ryu; Mi-Woon Kim
Journal:  Korean J Anesthesiol       Date:  2011-10-22

9.  Anesthesiologist's satisfaction using between cisatracurium and rocuronium for the intubation in the anesthesia induced by remifentanil and propofol.

Authors:  Hyunjung Lee; Sinho Jeong; Cheolhun Choi; Hyejin Jeong; Seongheon Lee; Seongwook Jeong
Journal:  Korean J Anesthesiol       Date:  2013-01-21

10.  Pharmacodynamics of cisatracurium in the intensive care unit: an observational study.

Authors:  Eric Dieye; Vincent Minville; Karim Asehnoune; Claude Conil; Bernard Georges; Pierre Cougot; Olivier Fourcade; Jean-Marie Conil
Journal:  Ann Intensive Care       Date:  2014-02-11       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.